75 related articles for article (PubMed ID: 15298082)
1. Mutations in the Myelin Protein Zero result in a spectrum of Charcot-Marie-Tooth phenotypes.
Kochański A
Acta Myol; 2004 May; 23(1):6-9. PubMed ID: 15298082
[TBL] [Abstract][Full Text] [Related]
2. Myelin protein zero mutation-related hereditary neuropathies: Neuropathological insight from a new nerve biopsy cohort.
Bremer J; Meinhardt A; Katona I; Senderek J; Kämmerer-Gassler EK; Roos A; Ferbert A; Schröder JM; Nikolin S; Nolte K; Sellhaus B; Popzhelyazkova K; Tacke F; Schara-Schmidt U; Neuen-Jacob E; de Groote CC; de Jonghe P; Timmerman V; Baets J; Weis J
Brain Pathol; 2024 Jan; 34(1):e13200. PubMed ID: 37581289
[TBL] [Abstract][Full Text] [Related]
3. Complete Loss of Myelin protein zero (MPZ) in a patient with a late onset Charcot-Marie-Tooth (CMT).
Gharesouran J; Hosseinzadeh H; Naghiloo A; Ghafouri-Fard S; Hussen BM; Taheri M; Rezazadeh M; Samadian M
Metab Brain Dis; 2023 Aug; 38(6):1963-1970. PubMed ID: 36952089
[TBL] [Abstract][Full Text] [Related]
4. Homomeric interactions of the MPZ Ig domain and their relation to Charcot-Marie-Tooth disease.
Ptak CP; Peterson TA; Hopkins JB; Ahern CA; Shy ME; Piper RC
Brain; 2023 Dec; 146(12):5110-5123. PubMed ID: 37542466
[TBL] [Abstract][Full Text] [Related]
5. Structural bases for the Charcot-Marie-Tooth disease induced by single amino acid substitutions of myelin protein zero.
Sakakura M; Tanabe M; Mori M; Takahashi H; Mio K
Structure; 2023 Nov; 31(11):1452-1462.e4. PubMed ID: 37699394
[TBL] [Abstract][Full Text] [Related]
6. Calcineurin Activity Is Increased in Charcot-Marie-Tooth 1B Demyelinating Neuropathy.
Sidoli M; Reed CB; Scapin C; Paez P; Cavener DR; Kaufman RJ; D'Antonio M; Feltri ML; Wrabetz L
J Neurosci; 2021 May; 41(20):4536-4548. PubMed ID: 33879538
[TBL] [Abstract][Full Text] [Related]
7. Thr124Met myelin protein zero mutation mimicking motor neuron disease.
Bisogni G; Romano A; Conte A; Tasca G; Bernardo D; Luigetti M; Di Paolantonio A; Fabrizi GM; Patanella AK; Meleo E; Sabatelli M
Amyotroph Lateral Scler Frontotemporal Degener; 2022 May; 23(3-4):299-304. PubMed ID: 34210210
[TBL] [Abstract][Full Text] [Related]
8. Emerging Therapies for Charcot-Marie-Tooth Inherited Neuropathies.
Stavrou M; Sargiannidou I; Georgiou E; Kagiava A; Kleopa KA
Int J Mol Sci; 2021 Jun; 22(11):. PubMed ID: 34205075
[TBL] [Abstract][Full Text] [Related]
9. Case report: A novel variant (H49N) in
Cao GH; Zhao MF; Dong Y; Fan LL; Liu YH; Deng Y; Tang LL
Front Neurol; 2024; 15():1319962. PubMed ID: 38481944
[TBL] [Abstract][Full Text] [Related]
10. Clinical Worsening of Charcot-Marie-Tooth Disease Due to Overlapping Acute Inflammatory Polyneuropathy.
Pinto J; Santos M; Matos D; Ferreira A; Santos AF
Cureus; 2023 Oct; 15(10):e47750. PubMed ID: 38021856
[TBL] [Abstract][Full Text] [Related]
11. Axonal Charcot-Marie-Tooth disease due to COQ7 mutation: expanding the genetic and clinical spectrum.
Zhang XY; Dong HL; Wu ZY
Brain; 2023 Dec; 146(12):e117-e119. PubMed ID: 37343138
[No Abstract] [Full Text] [Related]
12. Beware next-generation sequencing gene panels as the first-line genetic test in Charcot-Marie-Tooth disease.
Record CJ; Pipis M; Poh R; Polke JM; Reilly MM
J Neurol Neurosurg Psychiatry; 2023 Apr; 94(4):327-328. PubMed ID: 36376020
[No Abstract] [Full Text] [Related]
13. A novel DHTKD1 variant is associated with an atypical form of Charcot-Marie-Tooth disease type 2Q?
Matteoni E; Canosa A; Chiò A; Moglia C; Gallone S
Acta Neurol Belg; 2024 Apr; 124(2):693-694. PubMed ID: 37907797
[No Abstract] [Full Text] [Related]
14. Charcot-Marie-Tooth Disease Type 2-Like Phenotype due to a Novel Variant in the Stalk Domain of
Liouta E; Poulidou V; Frontistis A; Moschou M; Fidani S; Papoulidis I; Spilioti M; Kimiskidis VK; Arnaoutoglou M
Neurol India; 2023; 71(3):577-579. PubMed ID: 37322770
[No Abstract] [Full Text] [Related]
15. Reply to "SARS1 (SerRS) Causing De Novo Dominant Charcot-Marie-Tooth Disease with Slow Conduction".
He J; Liu XX; Fan DS; Chen WJ
Ann Neurol; 2023 Dec; 94(6):1189. PubMed ID: 37703427
[No Abstract] [Full Text] [Related]
16. SARS1 (SerRS) Causing De Novo Dominant Charcot-Marie-Tooth Disease with Slow Conduction.
Record CJ; Skorupinksa M; Zuchner S; Blake J; Reilly MM
Ann Neurol; 2023 Dec; 94(6):1187-1188. PubMed ID: 37706277
[No Abstract] [Full Text] [Related]
17. Knockdown of SIRT2 Rescues YARS-induced Charcot-Marie-Tooth Neuropathy in Drosophila.
Li X; Wang M; Gao X; Li C; Chen C; Qi Y; Wan Y; Yu W
Neurosci Bull; 2024 Apr; 40(4):539-543. PubMed ID: 38066253
[No Abstract] [Full Text] [Related]
18. Differentiating Charcot-Marie-Tooth disease from chronic inflammatory demyelinating polyradiculoneuropathy: neurophysiology is not the only clue.
Sommer C
Eur J Neurol; 2023 Dec; 30(12):3642. PubMed ID: 37410578
[No Abstract] [Full Text] [Related]
19. Could some mutations of the KIF5A gene be responsible for a dominant CMT2 phenotype? (Case report).
Dellatte J; Lievens I; Wang FC
Acta Neurol Belg; 2023 Dec; 123(6):2435-2438. PubMed ID: 37084037
[No Abstract] [Full Text] [Related]
20. Safety of anti-IL-23 risankizumab treatment in a patient with severe psoriasis and Charcot-Marie-Tooth disease.
Carugno A; Brigenti N; Gisondi P; Al Ghadban Z; Parietti M; Vezzoli P; Sena P; Pisciotta C
Australas J Dermatol; 2023 Nov; 64(4):e376-e378. PubMed ID: 37698028
[No Abstract] [Full Text] [Related]
[Next] [New Search]
